西酞普兰联合丙戊酸钠对复发双相障碍抑郁发作患者认知功能及血清炎症因子的影响

目的 探讨氢溴酸西酞普兰片联合丙戊酸钠对复发双相障碍抑郁发作患者认知功能及血清炎症因子的影响，分析其可能作用机制。方法 选择2014年7月-2015年12月收治的复发双相情感障碍抑郁发作患者104例为研究对象，采用随机数字表法分为观察组和对照组各52例，对照组给予丙戊酸钠治疗，观察组给予氢溴酸西酞普兰片联合丙戊酸钠治疗，治疗8周后，比较两组情绪状态、认知功能、血清炎症因子等指标。结果 治疗前，两组患者HAMD评分、BPMS评分比较无统计学意义；治疗8周后，两组患者的HAMD评分、BPMS评分均明显低于同组治疗前，差异有统计学意义（P<0.01）；且观察组HAMD评分、BPMS评分明显低于对照组，差异有统计学意义（P<0.01）。治疗前，两组患者TMT-A、TMT-B时间比较统计学意义；治疗8周，两组患者的TMT-A、TMT-B时间均明显短于同组治疗前，差异有统计学意义（P<0.05）；观察组患者TMT-A、TMT-B时间明显短于对照组，差异有统计学意义（P<0.05）。治疗前，两组患者血清中MIF、IL-1β、IL-6的含量比较无统计学意义；治疗8周，两组患者血清中MIF、IL-1β、IL-6的含量均明显低于同组治疗前，差异有统计学意义（P<0.05）；观察组血清中MIF、IL-1β、IL-6的含量明显低于对照组，差异有统计学意义（P<0.05）。结论 氢溴酸西酞普兰片有助于缓解复发双相障碍抑郁发作患者临床症状，改善认知功能，可能与抑制血清炎症因子表达有关。

Effect of citalopram hydrobromide tablets on cognitive function and inflammatory factors in patients with recurrent bipolar disorder

Objective To investigate the effect of citalopram hydrobromide tablets on cognitive function and inflammatory factors in patients with recurrent bipolar disorder (BPD), and to analyze its possible mechanism of action. Methods 104 patients with recurrent BPD in our hospital from July 2014 to December 2015 were selected, and they were divided into observation group and control group by random number table, 52 cases in each group. Control group was given sodium valproate, while observation group was given citalopram hydrobromide tablets and sodium valproate. After 8-week treatment, the emotional state, cognitive function, inflammatory factors were compared between the two groups. Results Before treatment, HAMD score, BPMS score of two groups were not statistically significant. After 8 weeks of treatment, HAMD score and BPMS score of two groups were significantly lower than those in the same group before treatment (P < 0.01); and the observation group HAMD score and BPMS score were significantly lower than the control group (P < 0.01). Before treatment, TMT-A, TMT-B time of two groups were not statistically significant. After 8 weeks of treatment, TMT-A and TMT-B time of two groups were significantly shorter than the same group before treatment (P < 0.05). TMT-A TMT-B in the observation group were significantly shorter than the control group (P < 0.05). The content of serum MIF, IL-1 beta and IL-6 in two groups before treatment were not statistically significant. After 8 weeks of treatment, the contents of MIF, IL-1 beta, IL-6 in two groups were significantly lower than the same group before treatment (P < 0.05). And the levels of serum MIF, IL-1 beta, IL-6 in observation group were significantly lower than the control group (P < 0.05). Conclusion Citalopram hydrobromide tablets can relieve clinical symptoms, improve cognitive function, and it possibly has relations with inhibiting the expression of inflammatory factors.